RNAZ (TransCode Therapeutics) Dividends Received


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $8.79
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.79
Price